Investing in Genomics: Why This VC Went for Diagnostics | GenomeWeb

There is no question that tough times are ahead for major pharmaceutical companies. In addition to general economic woes, big pharma is facing some unprecedented challenges all its own. Industry analysts estimate that branded drugs with nearly $30 billion of annual sales will lose patent protection over the next three years. Pharmaceutical pipelines are at historic lows and the industry has not seen a drug with sales in excess of $1 billion since Vioxx in 1999.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.